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Background
Cervicovaginal (CV) tissue is the primary site for HIV
transmission and a major reservoir for viral replication.
Therefore, a successful vaccine strategy should induce
potent immune responses at this mucosal surface. One
potential method for achieving a localised immune
response is to administer the antigen directly to the CV tis-
sue (Marx et al., 1993, Wassen et al., 1996). The aim of the
study was to evaluate the in vitro release characteristics of
lyophilised hydroxypropylmethylcellulose (HPMC) gel
inserts containing HIV envelope protein CN54gp140
either as stand-alone formulations or located within a
novel rod-insert vaginal ring device (RIVR).
Methods
Vaginal gel formulations comprising either low or high
molecular weight (MW) HPMC and CN54gp140 (0.25%
w/w) were prepared. The gels were injected into silicone
elastomer tubing, cut to 40 mm lengths, and then
lyophilised to produce solid rod inserts. In vitro release
testing was performed on rod inserts alone and rod insert
vaginal rings (RIVRs) containing two CN54gp140-loaded
rod inserts. Release of gp140 was quantified by ELISA.
Results
Release of CN54gp140 from rods prepared from low MW
HPMC was similar for both inserts alone and rings con-
taining inserts (99% cf. 90% over two hr). Release from
the high MW inserts was significantly slower and more
sustained than the low MW formulations. Also,
CN54gp140 release from high MW rod inserts rings (68%
of theoretical over 48 hr) was significantly more sustained
than high MW inserts alone (86% over 24 hr).
Conclusion
The study demonstrates that CN54gp140 (i) maintains its
antigenicity during the preparation of HPMC lyophilised
rod inserts, and (ii) may be administered in a sustained
manner when the inserts are placed into an RIVR device.
This stable, sustained-release formulation strategy has the
potential to induce stronger immune responses and
immune memory upon vaginal administration (Zhao and
Leong, 1996; Lofthouse, 2002).
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